Selected article for: "acute sars respiratory syndrome and adjuvant vaccine"

Author: Park, Kyung Soo; Sun, Xiaoqi; Aikins, Marisa E.; Moon, James J.
Title: Non-viral COVID-19 vaccine delivery systems
  • Cord-id: 3fyzk1wz
  • Document date: 2020_12_17
  • ID: 3fyzk1wz
    Snippet: The novel corona virus termed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread throughout the globe at a formidable speed, causing tens of millions of cases and more than one million deaths in less than a year of its report in December 2019. Since then, companies and research institutions have raced to develop SARS-CoV-2 vaccines, ranging from conventional viral and protein-based vaccines to those that are more cutting edge, including DNA- and mRNA-based vaccines. Each vac
    Document: The novel corona virus termed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread throughout the globe at a formidable speed, causing tens of millions of cases and more than one million deaths in less than a year of its report in December 2019. Since then, companies and research institutions have raced to develop SARS-CoV-2 vaccines, ranging from conventional viral and protein-based vaccines to those that are more cutting edge, including DNA- and mRNA-based vaccines. Each vaccine exhibits a different potency and duration of efficacy, as determined by the antigen design, adjuvant molecules, vaccine delivery platforms, and immunization method. In this review, we will introduce a few of the leading non-viral vaccines that are under clinical stage development and discuss delivery strategies to improve vaccine efficacy, duration of protection, safety, and mass vaccination.

    Search related documents:
    Co phrase search for related documents
    • addition development adjuvant and adjuvant addition: 1